The Madras High Court has cleared a government proposal to exclude a technical member of the Intellectual Property Appellate Board (IPAB) from hearing Swiss drug giant Novartis’ appeal against the rejection of patent for its anti-cancer drug Glivec. Chief justice AP Shah and justice V Ramasubramanian okayed leaving out S Chandrasekaran, former controller general of patents, from the panel and letting IPAB’s chairman and vice-chairman hear the appeal.
...
Novartis, which in August had filed a petition insisting that Mr Chandrasekaran should not hear its appeal as he had refused the Glivec patent in the first place, welcomed the development. The proposal was approved by all interested parties except Natco Pharma.
...
Novartis, which in August had filed a petition insisting that Mr Chandrasekaran should not hear its appeal as he had refused the Glivec patent in the first place, welcomed the development. The proposal was approved by all interested parties except Natco Pharma.
To me this is an 'interesting' decision simply because the Appeal Board will now give a technical decision without a technical member deciding the same...
I am just speechless and also the fact that I do not want to PUKE right now...
Readers who want to have a thourough back ground into this matter would do well to visit the Economic Times link above and more importantly visit this article by friend, Shamnad.
No comments:
Post a Comment